Syros Pharmaceuticals

Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Syros Pharmaceuticals (SYRS) to Neutral from Buy with a price target of $1, down from $6, after the company announced that the Phase 3 SELECTMDS-1 trial, which evaluated tamibarotene combined with azacitidine for newly diagnosed,

Business Insider · 2d

Syros Pharmaceuticals (SYRS) was downgraded to a Hold Rating at TD Cowen

Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from TD Cowen analyst Phil Nadeau yesterday. The

Seeking Alpha on MSN · 2d

Syros cut to neutral by H.C. Wainwright on failed drug study

H.C. Wainwright has downgraded Syros Pharmaceuticals (NASDAQ:SYRS) to neutral from buy, citing Tuesday’s announcement that a Phase 3 study of the company’s drug tamibarotene had failed to meet its primary endpoint.

Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default

Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...

Zacks.com on MSN1d

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal

Shares of Syros Pharmaceuticals SYRS plunged 86.9% on Wednesday after a late-stage study of its only pipeline candidate, ...

Yahoo Finance2d

Syros stock craters after lead cancer therapy flops in Phase III trial

Syros Pharmaceuticals’ stock has declined sharply for the second time in the past three months as a Phase III trial with ...

BioSpace2d

Syros Crashes Over 90% on Late-Stage MDS Fail, Loan Default

With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on ...

Hosted on MSN1d

Brookline Capital Downgrades Syros Pharmaceuticals (SYRS)

Fintel reports that on November 13, 2024, Brookline Capital downgraded their outlook for Syros Pharmaceuticals ...

Syros Pharmaceuticals Shares Plummet Premarket After Study Failure

Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer.

FierceBiotech2d

Syros flunks phase 3 blood cancer trial, triggering loan default and share-price plunge

Syros Pharmaceuticals’ blood cancer prospect tamibarotene has failed another study, triggering a default on a loan and ...

Syros Stock - Investors of Syros Pharmaceuticals Encouraged to Contact Kehoe Law Firm, P.C. - SYRS

Philadelphia, Pennsylvania-- (Newsfile Corp. - November 13, 2024) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or ...

BioWorld2d

No RARA, Syros trouble: MDS phase III sinks tamibarotene

Syros Pharmaceuticals Inc.’s phase III failure with oral retinoic acid receptor alpha agonist tamibarotene in myelodysplastic syndrome (MDS) meant not only severe stock damage but also defaulting on ...

Monthly Prescribing Reference1d

Tamibarotene Fails to Meet Primary Endpoint in Myelodysplastic Syndrome Trial

Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.

TipRanks on MSN2d

Syros downgraded to Market Perform from Outperform at JMP Securities

JMP Securities analyst Jason Butler downgraded Syros Pharmaceuticals (SYRS) to Market Perform from Outperform without a price target The firm cites the “disappointing results” from the Phase 3 ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Related topics